Company & Sponsor Intelligence

NeuroDerm Ltd.

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials4

Recruiting0

Completed4

Countries2

Therapeutic footprint

adhdparkinsons

Indexed studies

NCT01174355A Study of ND0801 in Attention Deficit/Hyperactivity Disorder (ADHD)
adhd · IsraelPHASE1, PHASE2

NCT02096601A Safety, Tolerability, and Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease Patients
parkinsons · IsraelPHASE1

NCT01103011Safety, Tolerability and Pharmacokinetic Profile of Levodopa Administered With Continuous Administration of ND0611
parkinsons · IsraelPHASE1

NCT02577523A Clinical Study of Efficacy, Safety, Tolerability and PK of ND0612H in Subjects With Advanced Parkinson's Disease
parkinsons · United StatesPHASE2

Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →